Assessment of the Potential Role of Active Vitamin D Treatment in Telomere Length: A Case-Control Study in Hemodialysis Patients

Clinical Therapeutics

Volumn 34, Issue 4, 2012, Pages 849-856

  Borras, Mercè ^a   Panizo, Sara ^b   Sarró, Felipe ^a   Valdivielso, Jose M ^b   Fernandez, Elvira ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b UNIVERSITY OF LLEIDA   (Spain)

Author keywords

Kidney disease; Senescence

Indexed keywords

VITAMIN D;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; SOUTHERN BLOTTING; TELOMERE HOMEOSTASIS;

CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TELOMERE; VITAMIN D;

EID: 84859590035     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.016     Document Type: Article

References (32)

1. Fuster J.J., Andres V. Telomere biology and cardiovascular disease. Circ Res 2006, 99:1167-1180.
2. Jeanclos E., Schork N.J., Kyvik K.O., et al. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension 2000, 36:195-200.
3. Benetos A., Okuda K., Lajemi M., et al. Telomere length as an indicator of biological aging-the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001, 37:381-385.
4. Jeanclos E., Krolewski A., Skurnick J., et al. Shortened telomere length in white blood cells of patients with IDDM. Diabetes 1998, 47:482-486.
5. Brouilette S., Singh R.K., Thompson J.R., et al. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 2003, 23:842-846.
6. Samani N.J., Boultby R., Butler R., et al. Telomere shortening in atherosclerosis. Lancet 2001, 358:472-473.
7. Aviv H., Khan M.Y., Skurnick J., et al. Age dependent aneuploidy and telomere length of the human vascular endothelium. Atherosclerosis 2001, 159:281-287.
8. Ogami M., Ikura Y., Ohsawa M., et al. Telomere shortening in human coronary artery diseases. Arterioscler Thromb Vasc Biol 2004, 24:546-550.
9. Matthews C., Gorenne I., Scott S., et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis-effects of telomerase and oxidative stress. Circ Res 2006, 99:156-164.
10. Urbanek K., Quaini F., Tasca G., et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc Natl Acad Sci U S A 2003, 100:10440-10445.
11. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2003, US Renal Data System, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease, Bethesda, Md.
12. Foley R.N., Parfrey P.S., Sarnak M.K. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(Suppl 3):S112-S119.
13. Ramirez R., Carracedo J., Soriano S., et al. Stress-induced premature senescence in mononuclear cells from patients on long-term hemodialysis. Am J Kidney Dis 2005, 45:353-359.
14. Tsirpanlis G., Chatzipanagiotou S., Boufidou F., et al. Telomerase activity is decreased in peripheral blood mononuclear cells of hemodialysis patients. Am J Nephrol 2006, 26:91-96.
15. Walters M.R. Newly identified actions of the vitamin D endocrine system. Endocr Rev 1992, 13:719-764.
16. Welsh J., Simboli-Campbell M., Narvaez C.J., Tenniswood M. Role of apoptosis in the growth inhibitory effects of vitamin D in MCF-7 cells. Adv Exp Med Biol 1995, 375:45-52.
17. Manolagas S.C., Hustmyer F.G., Yu X.P. Immunomodulating properties of 1,25-dihydroxyvitamin-D3. Kidney Int Suppl 1990, 29:S9-S16.
18. Craver L., Marco M.P., Martinez I., et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007, 22:1171-1176.
19. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16:1115-1125.
20. Valdivielso J.M., Coll B., Fernandez E. Vitamin D and the vasculature: can we teach an old drug new tricks?. Expert Opin Ther Targets 2009, 13:29-38.
21. Kimura M., Stone R.C., Hunt S.C., et al. Measurement of telomere length by the Southern blot analysis of terminal restriction fragment lengths. Nat Protoc 2010, 5:1596-1607.
22. Rajski S.R., Williams R.M. DNA cross-linking agents as antitumor drugs. Chem Rev 1998, 98:2723-2796.
23. Cherif H., Tarry J.L., Ozanne S.E., Hales C.N. Ageing and telomeres: a study into organ- and gender-specific telomere shortening. Nucleic Acids Res 2003, 31:1576-1583.
24. Yamada O., Takanashi M., Ujihara M., Mizoguchi H. Down-regulation of telomerase activity is an early event of cellular differentiation without apparent telomeric DNA change. Leukemia Res 1998, 22:711-717.
25. Jiang F., Bao J.Y., Li P.F., et al. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D-3 through the down-regulation of telomerase. J Biol Chem 2004, 279:53213-53221.
26. Richards J.B., Valdes A.M., Gardner J.P., et al. Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women. Am J Clin Nutr 2007, 86:1420-1425.
27. Mathieu C., Adorini L. The coming of age of 1,25-dihydroxyvitamin D-3 analogs as immunomodulatory agents. Trends Mol Med 2002, 8:174-179.
28. Yee Y.K., Chintalacharuvu S.R., Lu J., Nagpal S. Vitamin D receptor modulators for inflammation and cancer. Mini Rev Med Chem 2005, 5:761-778.
29. Deluca H.F., Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J 2001, 15:2579-2585.
30. Spittle M.A., Hoenich N.A., Handelman G.J., et al. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001, 38:1408-1413.
31. Carracedo J., Ramirez R., Soriano S., et al. Monocytes from dialysis patients exhibit characteristics of senescent cells: does it really mean inflammation?. Contrib Nephrol 2005, 149:208-218.
32. Block G.A., Klassen P.S., Lazarus J.M., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.